Joachim Grüner

Learn More
In 2006, levetiracetam was approved as the first of the newer anticonvulsive drugs as an intravenous formulation (ivLEV) for patients with epileptic seizures who are unable to take oral medication. We report our experience with the use of ivLEV for the treatment of 18 episodes of benzodiazepine refractory focal status epilepticus (SE) in 16 patients,(More)
30 min after the administration of 200 µg TRH i.v. the increment of the TSH levels over basal levels (Δ TSH 30 min) was studied in 49 patients with nontoxic goiter. Δ TSH 30 min was within the normal range of controls (n=47, mean±2 SD: 2.73–23.60 µU/ml, log. distribution) in the first goiter group of 38 cases (log. mean: 10.40 µU/ml). In the remaining 11(More)
62 Nierenbiopsien mit der ausschließlichen Diagnose: benigne Nephrosklerose bzw. Übergang von benigner Nephrosklerose in sekundäre maligne Nephrosklerose wurden untersucht. Morphologische Befunde (relatives Interstitiumvolumen der Nierenrinde, Arten glomerulärer Hyalinisierung und periglomerulärer Veränderungen sowie Gefäßindex) wurden miteinander und mit(More)
BACKGROUND Urine ethyl glucuronide (EtG) is considered as a specific marker of recent ethanol consumption. We describe false-positive DRI(®) EIA EtG enzyme immunoassay results caused by propyl glucuronides in urine after using a propanol-based hand sanitizer. METHODS EtG screening was done with the DRI(®) EIA EtG assay (Microgenics), using a cut-off of(More)
BACKGROUND Urine-ethyl glucuronide (EtG) concentrations are considered as a specific marker of recent alcohol consumption. We describe false-positive EtG screening results by the DRI ethyl glucuronide enzyme immunoassay caused by chloral hydrate intake. METHODS Urine-EtG-screening: DRI EtG enzyme immunoassay (Thermo Fisher Scientific Microgenics) on a(More)
The literature on lithium treatment during chronic dialysis is reviewed and a new case presented. In a patient suffering from bipolar affective disorder, onset of hemodialysis precipitated a manic episode. Oral lithium, given in single postdialysis doses, was well-tolerated, effective, and easy to handle. During 19 months of constant dosing, 10.8 mEq after(More)